Nasdaq

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...
Seeking Alpha

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA ...
Drug Store News

Amneal receives FDA nod for generic Risperdal Consta

Amneal has received the Food and Drug Administration’s approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which is the generic of ...
Fierce Healthcare

LegalView Creates New Informational Practice Areas for Possibly Unsafe Drugs Risperdal and Dostinex

LegalView.com would like to inform readers of its newly launched information portal dealing with the possibly unsafe prescription drugs Dostinex and Risperdal. Each of these information portals ...
Becker's Hospital Review

J&J to Pay $2.2B Settlement to End Risperdal Probes

J&J to Pay $2.2B Settlement to End Risperdal Probes New Brunswick, N.J.-based Johnson & Johnson has agreed to pay up to $2.2 billion to settle U.S. investigations and lawsuits regarding its marketing ...
Nasdaq

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients ...

While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile. Hyperglycemia and diabetes mellitus (DM): in some cases extreme and ...